首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   83037篇
  免费   6737篇
  国内免费   4122篇
耳鼻咽喉   2055篇
儿科学   452篇
妇产科学   2904篇
基础医学   5051篇
口腔科学   836篇
临床医学   9069篇
内科学   5947篇
皮肤病学   846篇
神经病学   837篇
特种医学   5028篇
外国民族医学   65篇
外科学   15894篇
综合类   14618篇
现状与发展   5篇
预防医学   2204篇
眼科学   412篇
药学   3623篇
  22篇
中国医学   481篇
肿瘤学   23547篇
  2024年   130篇
  2023年   816篇
  2022年   1548篇
  2021年   2236篇
  2020年   2186篇
  2019年   1936篇
  2018年   1784篇
  2017年   2166篇
  2016年   2803篇
  2015年   2494篇
  2014年   4780篇
  2013年   4233篇
  2012年   5281篇
  2011年   5902篇
  2010年   5091篇
  2009年   4912篇
  2008年   4832篇
  2007年   5355篇
  2006年   5050篇
  2005年   4937篇
  2004年   3878篇
  2003年   3431篇
  2002年   2939篇
  2001年   2824篇
  2000年   2309篇
  1999年   1764篇
  1998年   1534篇
  1997年   1357篇
  1996年   872篇
  1995年   764篇
  1994年   659篇
  1993年   410篇
  1992年   379篇
  1991年   345篇
  1990年   287篇
  1989年   265篇
  1988年   246篇
  1987年   205篇
  1986年   187篇
  1985年   156篇
  1984年   124篇
  1983年   80篇
  1982年   90篇
  1981年   81篇
  1980年   79篇
  1979年   46篇
  1978年   37篇
  1977年   29篇
  1976年   24篇
  1975年   10篇
排序方式: 共有10000条查询结果,搜索用时 906 毫秒
101.
分析原发性腹膜后恶性肿瘤12例。83%以腹块和腹痛为主要症状,体征中腹块占91.5%,以恶性淋巴瘤居首位占61%。全组完全切除率为58%,行脏器联合切除占25%。完全切除加放疗、化疗3年存活率为28.5%,部分切除及活检未给其它治疗者5例预后差,均1年内死亡,差别显著。  相似文献   
102.
Summary Eight patients with malignant gliomas verified on CT scan, received an intravenous injection of 50 mg of Adriamycin R, 24 hours prior to surgical removal of the tumour. Peroperatively, both tumour and surrounding tissue specimens were obtained for determination of the tissue concentrations of Adriamycin and its reduced metabolite Adriamycinol. It was found that Adriamycin could be detected in tumour tissue from all patients. The concentration varied between 0,9 and 4,6 nmol/g tissue. In contrast, Adriamycin could only be detected in surrounding brain tissue from one patient.In anin vitro study a human malignant glioma cell line (U-251 MG) was exposed to various concentrations of Adriamycin for 24 hours. It was found that an intracellular drug concentration above 30 nmol/g cells caused a concentration dependent inhibition of cell growth. Thus, it is likely that the poor effect of Adriamycin on patients with malignant gliomas is due to an ineffective drug accumulation in the tumour tissue.  相似文献   
103.
104.
Image-directed color Doppler ultrasonography (ICDUS) studies of 86 patients with superficial solid masses yielded significantly lower resistive index (RI) values in acute inflammatory lesions, but no significant difference between the maximum systolic flow velocities (S) of the patient groups with malignant, benign, and acute inflammatory lesions. When analyzed separately, the malignant soft-tissue tumor subgroup was shown to have significantly higher mean RI compared to that of the malignant node subgroup. We conclude that RI may be useful in the differentiation of acute inflammatory masses from other pathological entities. Malignant soft-tissue tumors, especially sarcomas, may have different Doppler features from those of carcinomatous tumors. © 1995 John Wiley & Sons, Inc.  相似文献   
105.
Dantrolene seems to be the causal therapy in malignant hyperthermia (MH) crisis but the complex mechanisms of MH and dantrolene therapy are still not fully understood. The influence of dantrolene on ryanodine-induced contractures has been reported in animal studies only. In the present study 20 patients from] 7 families were tested for MH using the protocol of the European Malignant Hyperthermia Group. In addition ryanodine-induced contractures were evaluated following bolus application of 10.0 μmol · 1-1 ryanodine. After pretreatment with 1 μimol · 1-1 dantrolene ryanodine-provoked contractures developed significantly later in MHS (15.8±1.8 min) and MHN (46.0±4.2 min) muscle specimens than after ryanodine alone (MHS 4.8±0.7 min), (MHN 13.7±0.9 min). They were no longer observed in either group after pretreatment with 5 μimol · 1-1 dantrolene. We conclude that dantrolene is able to attenuate ryanodine-induced contractures dose-dependendy, and therefore it is speculated that dantrolene could specifically act at the ryanodine receptor binding site.  相似文献   
106.
卵巢恶性肿瘤与血小板增多关系分析   总被引:1,自引:0,他引:1  
目的探讨卵巢恶性肿瘤伴发血小板增多的临床规律。方法回顾分析98例卵巢恶性肿瘤患者的临床资料,26例合并血小板增多。结果血小板增多占26.5%,其中晚期(Ⅲ+Ⅳ期)占88.46%,晚期患者血小板偏高明显增多,且肿瘤切除后血小板下降。结论卵巢恶性肿瘤伴发血小板增多晚期患者多见,预后差,血小板增多可作为判断卵巢肿瘤恶性程度及术后随访的指标。  相似文献   
107.
108.
[目的]观察比较异环磷酰胺(IFO)、顺铂(DDP)、5-氟尿嘧啶(5-Fu)联合方案(IPF方案)与DDP,5-Fu(PF方案)治疗晚期复发鼻咽癌(Ⅲ-Ⅳ期)的近期疗效及毒副反应。[方法]136例均经病理证实为晚期复发鼻咽癌患者,随机分为IPF组69例,PF组67例(对照组)[结果]IPF组和PF组有效率分别为69.56%(48/69)和43.3%(29/67),两组间差异有显著性(X2=8.519,P<0.01)。中位生存期:IPF组16个月(8-34个月),PF组为6.5个月(4-21个月),两组间差异有显著性(X2=22.36,P<0.05)。毒副作用主要为骨髓抑制,Ⅲ-Ⅳ度白细胞下降率IPF组为49.4%,PF组为5.97%,两组差异有显著性(X2=29.54,P<0.01)。Ⅲ-Ⅳ度血小板下降率IPF组为29.18%,PF组为0%(X2=30.29,P<0.01);Ⅲ-Ⅳ度消化道反应两组的发生率分别为15.94%和11.94%(x2=0.234,P>0.01).且以Ⅲ度为主。[结论]以IFO为主的方案联合治疗晚期复发鼻咽癌疗效好,毒副反应能耐受,可作为一线方案。  相似文献   
109.
贲门癌术中留置金属导芯硅胶鼻肠管的临床研究   总被引:1,自引:0,他引:1  
目的探讨贲门癌术后早期肠内营养的可行性、安全性及临床效果.方法贲门癌患者术中留置金属导芯硅胶鼻饲管,术后第1天开始肠内营养支持,术前及术后第10天,分别测量体重,检测血红蛋白浓度及肝肾功能,观察肠内营养的副作用.结果全组鼻饲管留置时间平均15.2 d;术后早期肠内营养明显增加了营养物质的摄入量,术后无明显的体重丢失,未见需要终止治疗的并发症.结论早期肠内营养治疗具有符合生理、减少医药费用等优点,该置管方法安全、简便,达到了加强术后患者营养支持的目的,可列入术后常规应用.  相似文献   
110.
A case of papilliferous keratoameloblastoma is reported which is only the second ever documented. The patient was a 76-yr-old black woman with a large expansile multilocular radiolucency of the body, angle and ramus of the mandible. Histologically the lesion consisted of sheets of cystic follicles filled with necrotic debris and sometimes parakeratin. The vast majority of the follicles were lined by a papilliferous epithelium consisting of large rounded cells with centrally placed nuclei. True papillary projections with cores of connective tissue were also present. The remainder of the follicles were lined by a thin parakeratinising stratified squamous epithelium. Histological features characteristic of ameloblastoma were absent. Final classification of these lesions will have to await the reporting of further cases.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号